We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The Royal Pharmaceutical Society of Great Britain (RPS) has made new recommendations to increase the use of pharmacist independent prescribers (PIP) in the UK.
Sensorion has received acceptance from the European Medicines Agency (EMA) on its Paediatric Investigation Plan (PIP) for Arazasetron (SENS-401) in two indications.